Generation Bio Co. (NASDAQ:GBIO) Short Interest Down 6.1% in September

Generation Bio Co. (NASDAQ:GBIO) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 2,010,000 shares, a decrease of 6.1% from the September 15th total of 2,140,000 shares. Based on an average trading volume of 104,700 shares, the days-to-cover ratio is presently 19.2 days. Currently, 4.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

GBIO has been the topic of a number of analyst reports. Wedbush restated an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research note on Thursday, August 8th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Generation Bio in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.50.

Institutional Trading of Generation Bio

A number of large investors have recently added to or reduced their stakes in the company. PFG Advisors bought a new position in shares of Generation Bio in the 1st quarter valued at about $41,000. SG Americas Securities LLC purchased a new stake in Generation Bio during the third quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Generation Bio in the 1st quarter valued at approximately $74,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Generation Bio by 91.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after purchasing an additional 9,075 shares during the period. Finally, American Century Companies Inc. increased its position in shares of Generation Bio by 199.3% during the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock valued at $90,000 after purchasing an additional 21,167 shares during the last quarter. Institutional investors own 95.22% of the company’s stock.

Generation Bio Stock Up 1.7 %

NASDAQ GBIO traded up $0.04 on Wednesday, reaching $2.46. The company had a trading volume of 112,779 shares, compared to its average volume of 186,276. The stock has a market capitalization of $163.66 million, a PE ratio of -0.96 and a beta of 2.80. Generation Bio has a 12 month low of $0.86 and a 12 month high of $4.65. The firm’s 50 day moving average price is $2.50 and its 200 day moving average price is $2.89.

Generation Bio (NASDAQ:GBIO) last issued its earnings results on Wednesday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $4.09 million during the quarter, compared to the consensus estimate of $3.23 million. Generation Bio had a negative return on equity of 92.86% and a negative net margin of 1,202.56%. On average, research analysts expect that Generation Bio will post -1.8 EPS for the current year.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.